YS Biopharma Co., Ltd.
YS · NASDAQ
3/31/2025 | 9/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $555 | $536 | $524 | $337 |
| - Cash | $28 | $49 | $246 | $223 |
| + Debt | $414 | $369 | $424 | $555 |
| Enterprise Value | $941 | $856 | $702 | $669 |
| Revenue | – | – | $136 | $169 |
| % Growth | – | – | -19.7% | – |
| Gross Profit | – | – | $34 | $134 |
| % Margin | – | – | 25.4% | 79.3% |
| EBITDA | – | – | -$83 | -$72 |
| % Margin | – | – | -61% | -42.9% |
| Net Income | – | – | -$181 | -$80 |
| % Margin | – | – | -133.9% | -47.5% |
| EPS Diluted | – | – | -1.81 | -0.85 |
| % Growth | – | – | -112.9% | – |
| Operating Cash Flow | – | – | $0 | $0 |
| Capital Expenditures | – | – | $0 | $0 |
| Free Cash Flow | – | – | $0 | $0 |